Antigenic breadth: A missing ingredient in HSV-2 subunit vaccines?

Expert Review of Vaccines

Volumn 13, Issue 6, 2014, Pages 691-710

  Halford, William P ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antigenic breadth; deletion of ICP0's nuclear localization signal; glycoprotein D; herpes simplex virus 2; infected cell protein 0; live HSV 2 vaccine; plaque forming unit; severe combined immunodeficiency

Indexed keywords

ACAM 529; ADENOVIRUS VECTOR; BCG VACCINE; CHICKENPOX VACCINE; GLYCOPROTEIN B; GLYCOPROTEIN D; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; LENTIVIRUS VECTOR; LIVE VACCINE; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; PLASMID DNA; POLIOMYELITIS VACCINE; POXVIRUS VECTOR; PROTEOME; SMALLPOX VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN; WART VIRUS VACCINE; YELLOW FEVER VACCINE; HERPES VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGENIC BREADTH; ANTIGENICITY; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GENITAL HERPES; GUINEA PIG; HEALTH HAZARD; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; LISTERIA MONOCYTOGENES; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN SUBUNIT; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; SALMONELLA TYPHIMURIUM; SEXUALITY; T LYMPHOCYTE; UNITED STATES; VACCINATION; VARICELLA ZOSTER VIRUS; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS GENOME; WESTERN BLOTTING; WILD TYPE; EPIDEMIOLOGY; HERPES GENITALIS; IMMUNOLOGY;

CLINICAL TRIALS AS TOPIC; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; HUMANS; UNITED STATES; VACCINES, ATTENUATED; VACCINES, SUBUNIT;

EID: 84901014093     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.910121     Document Type: Review

References (215)

1. Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest 2012; 121(12):4600-9
2. Dropulic LK, Cohen JI. The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines 2012;11(12):1429-40
3. Cohen J. Immunology. Painful failure of promising genital herpes vaccine. Science 2010;330(6002):304
4. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012;366(1):34-43
5. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347(21): 1652-61
6. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999;282(4): 331-40
7. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis 1997;176(5):1129-34
8. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343(8911): 1460-3
9. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 1990;161(4): 653-60
10. Watson RJ, Enquist LW. Genetically engineered herpes simplex virus vaccines. Prog Med Virol 1985;31:84-108
11. Watson RJ, Weis JH, Salstrom JS, Enquist LW. Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli. Science 1982;218(4570):381-4
12. Halford WP, Gebhardt BM. Host interferon: a silent partner in the regulation of herpes simplex virus latency. In: Mossman KL, editor. Viruses and interferon: current research. Horizon Scientific Press; Hethersett, UK: 2011. p. 85-11
13. Ledford H. Failed herpes vaccine puzzles virologists. Nature 2012;doi:10.1038/nature.2012.9739
14. Stanberry LR, Bernstein DI, Burke RL, et al. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155(5):914-20
15. McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996;93(21): 11414-20
16. Bourne N, Bravo FJ, Francotte M, et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003;187(4):542-9
17. Bourne N, Milligan GN, Stanberry LR, et al. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 2005;192(12):2117-23
18. Bernstein DI, Earwood JD, Bravo FJ, et al. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 2011;29(11):2071-8
19. Bernstein DI, Farley N, Bravo FJ, et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 2010; 28(21):3748-53
20. Laing KJ, Magaret AS, Mueller DE, et al. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol 2010;30(5):703-22
21. Gilman SC, Docherty JJ, Rawls WE. Antibody responses in humans to individual proteins of herpes simplex viruses. Infect Immun 1981;34(3):880-7
22. Laing KJ, Dong L, Sidney J, et al. Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol 2012;167(1):47-58
23. Posavad CM, Remington M, Mueller DE, et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 2010;184(6):3250-9
24. Hosken N, McGowan P, Meier A, et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol 2006; 80(11):5509-15
25. Koelle DM, Schomogyi M, McClurkan C, et al. CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VP5: comparison with responses to tegument and envelope glycoproteins. J Virol 2000;74(23):11422-5
26. Ashley R, Mack K, Critchlow C, et al. Differential effect of systemic acyclovir treatment of genital HSV-2 infections on antibody responses to individual HSV-2 proteins. J Med Virol 1988;24(3): 309-19
27. Ashley R, Mertz GJ, Corey L. Detection of asymptomatic herpes simplex virus infections after vaccination. J Virol 1987; 61(2):264-8
28. Ashley R, Mertz G, Clark H, et al. Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine. J Virol 1985;56(2):475-81
29. Wald A, Koelle DM, Fife K, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011;29(47):8520-9
30. Skoberne M, Cardin R, Lee A, et al. An adjuvanted herpes simplex virus type 2 (HSV-2) subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs. J Virol 2013;87(7):3930-42
31. Available from: http://www.antigenics.com/docs/press-releases/2013/herpv- vaccine-for-genital-herpes-meets-primary-endpoint.php 2013
32. Available from: http://www.genocea.com/publications/files/Interscience% 20Conference%20on%20Antimicrobial% 20Agents%20and%20Chemotherapy%20% 28ICAAC%29%20Denver%20CO, % 20September%2010-13, %202013.pdf 2013
33. Johnston C, Koelle DM, Wald A. Current status and prospects for development of an HSV vaccine. Vaccine 2014;32(14): 1553-60
34. Dasgupta G, Chentoufi AA, Nesburn AB, et al. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines 2009;8(8): 1023-35
35. Haddow LJ, Mindel A. Genital herpes vaccines-cause for cautious optimism. Sex Health 2006;3(1):1-4
36. Goel N, Zimmerman DH, Rosenthal KS. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Front Biosci 2005;10:966-74
37. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 2004;11(3): 437-45
38. Cunningham AL, Mikloska Z. The Holy Grail: immune control of human herpes simplex virus infection and disease. Herpes 2001;8(Suppl 1):6A-10A
39. Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000;30(3):549-66
40. Hall MJ, Katrak K. The quest for a herpes simplex virus vaccine: background and recent developments. Vaccine 1986;4(3): 138-50
41. Wenz C. Genital herpes: vaccines show the way. Nature 1983;303(5919):648-9
42. Gunby P. Genital herpes research: many aim to tame maverick virus. JAMA 1983; 250(18):2417-19; 2423-2414, 2427
43. Delagrave S, Hernandez H, Zhou C, et al. Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital model. PLoS One 2012;7(10):e46714
44. Awasthi S, Zumbrun EE, Si H, et al. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J Virol 2012;86(8):4586-98
45. Halford WP, Puschel R, Gershburg E, et al. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS One 2011;6(3): e17748
46. Hoshino Y, Pesnicak L, Dowdell KC, et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 2008;26(32):4034-40
47. Parr EL, Parr MB. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 1999;98(4):639-45
48. McDermott MR, Smiley JR, Leslie P, et al. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 1984;51(3):747-53
49. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006;344(1):230-9
50. Schrimpf JE, Tu EM, Wang H, et al. B7 costimulation molecules encoded by replication-defective, vhs-deficient HSV-1 improve vaccine-induced protection against corneal disease. PLoS One 2011; 6(8):e22772
51. Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997; 175(1):16-25
52. Vagvala SP, Thebeau LG, Wilson SR, Morrison LA. Virus-encoded b7-2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice. J Virol 2009; 83(2):953-60
53. Cohen JI. The varicella-zoster virus genome. Curr Top Microbiol Immunol 2010;342: 1-14
54. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008;197(Suppl 2): S165-9
55. Quinlivan M, Breuer J, Schmid DS. Molecular studies of the Oka varicella vaccine. Expert Rev Vaccines 2011;10(9): 1321-36
56. Halford WP, Puschel R, Rakowski B. Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS One 2010;5(8):e12251
57. Halford WP, Weisend C, Grace J, et al. ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency. Virol J 2006;3:44
58. Halford WP, Geltz J, Gershburg E. Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS One 2013;8(6):e65523
59. Hoshino Y, Dalai SK, Wang K, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005;79(1):410-18
60. Xu F, Gee JM, Naleway A, et al. Incidence of neonatal herpes simplex virus infections in two managed care organizations: implications for surveillance. Sex Transm Dis 2008;35(6):592-8
61. Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol 2007;196(1):43.e41-6
62. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296(8):964-73
63. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40(3):187-93
64. CDC. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years-United States 2005-2008. MMWR Morb Mortal Wkly Rep 2010; 59(15): 456-9
65. Gottlieb SL, Douglas JM Jr, Foster M, et al. Incidence of herpes simplex virus type 2 infection in 5 sexually transmitted disease (STD) clinics and the effect of HIV/STD risk-reduction counseling. J Infect Dis 2004;190(6):1059-67
66. Solomon L, Cannon MJ, Reyes M, et al. Epidemiology of recurrent genital herpes simplex virus types 1 and 2. Sex Transm Infect 2003;79(6):456-9
67. Scott DA, Coulter WA, Lamey PJ. Oral shedding of herpes simplex virus type 1: a review. J Oral Pathol Med 1997;26(10): 441-7
68. Buddingh GJ, Schrum DI, Lanier JC, Guidry DJ. Studies of the natural history of herpes simplex virus infections. Pediatrics 1953;11:593-605
69. Bertke AS, Patel A, Krause PR. Herpes simplex virus latency-associated transcript sequence downstream of the promoter influences type-specific reactivation and viral neurotropism. J Virol 2007;81(12):6605-13
70. Bren L. Genital herpes: a hidden epidemic. FDA Consum 2002;36(2):10-16
71. Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Pediatr Clin North Am 2013;60(2):351-65
72. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 2006;20(1): 73-83
73. Whitley RJ, Roizman B. Herpes simplex viruses: is a vaccine tenable? J Clin Invest 2002;110(2):145-51
74. Morein B, Merza M. Vaccination against herpesvirus, fiction or reality? Scand J Infect Dis 1991;80(Suppl):110-18
75. Centifanto-Fitzgerald YM, Rayfield M, Tian PY, Kaufman HE. Herpes simplex virus latency in the rabbit trigeminal ganglia: ganglionic superinfection. Proc Soc Exp Biol Med 1985;179(1):55-67
76. Centifanto-Fitzgerald YM, Varnell ED, Kaufman HE. Initial herpes simplex virus type 1 infection prevents ganglionic superinfection by other strains. Infect Immun 1982;35(3):1125-32
77. Meignier B, Norrild B, Roizman B. Colonization of murine ganglia by a superinfecting strain of herpes simplex virus. Infect Immun 1983;41(2):702-8
78. Sandstrom IK, Foster CS, Wells PA, et al. Previous immunization of mice with herpes simplex virus type-1 strain MP protects against secondary corneal infection. Clin Immunol Immunopathol 1986;40(2): 326-34
79. Thompson RL, Nakashizuka M, Stevens JG. Vaccine potential of a live avirulent herpes simplex virus. Microb Pathog 1986;1(4): 409-16
80. Parr MB, Parr EL. Protective immunity against HSV-2 in the mouse vagina. J Reprod Immunol 1997;36(1-2):77-92
81. Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 1998;160(12):6093-100
82. Morello CS, Kraynyak KA, Levinson MS, et al. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 2012;30(46):6541-50
83. Shlapobersky M, Marshak JO, Dong L, et al. Vaxfectin(R)-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol 2012;93:1305-15
84. Khodai T, Chappell D, Christy C, et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 2011;18(10):1702-9
85. Brans R, Yao F. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol 2010;10:163
86. Weir JP, Bennett M, Allen EM, et al. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J Gen Virol 1989;70(Pt 10): 2587-94
87. Chentoufi AA, Dasgupta G, Christensen ND, et al. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. J Immunol 2010;184(5):2561-71
88. Skinner GR, Turyk ME, Benson CA, et al. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med Microbiol Immunol (Berl) 1997;186(1): 31-6
89. Skinner GR, Buchan A, Hartley CE, et al. The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects. Med Microbiol Immunol 1980;169(1):39-51
90. Aurelian L, Kokuba H, Smith CC. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Vaccine 1999;17(15-16):1951-63
91. Orr MT, Orgun NN, Wilson CB, Way SS. Cutting Edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 2007;178(8): 4731-5
92. Meseda CA, Stout RR, Weir JP. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D. Viral Immunol 2006; 19(2):250-9
93. Zheng B, Graham FL, Johnson DC, et al. Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors. Vaccine 1993;11(12): 1191-8
94. Johnson DC. Adenovirus vectors as potential vaccines against herpes simplex virus. Rev Infect Dis 1991;13(Suppl 11): S912-16
95. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158(3):602-14
96. Mori I, Liu B, Goshima F, et al. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2. Microbes Infect 2005; 7(15):1492-500
97. Osorio Y, Ghiasi H. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes. J Virol 2003;77(10):5774-83
98. Veselenak RL, Shlapobersky M, Pyles RB, et al. Vaxfectin((R))-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 2012;30(49):7046-51
99. Domingo C, Gadea I, Pardeiro M, et al. Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D. Vaccine 2003; 21(25-26):3565-74
100. Dutton JL, Li B, Woo WP, et al. A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PLoS One 2013; 8(10):e76407
101. Chiuppesi F, Vannucci L, De Luca A, et al. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J Virol 2012; 86(12):6563-74
102. Natuk RJ, Cooper D, Guo M, et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 2006;80(9):4447-57
103. Mattion NM, Reilly PA, Camposano E, et al. Characterization of recombinant polioviruses expressing regions of rotavirus VP4, hepatitis B surface antigen, and herpes simplex virus type 2 glycoprotein D. J Virol 1995;69(8):5132-7
104. Heineman TC, Connelly BL, Bourne N, et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995;69(12):8109-13
105. Karem KL, Bowen J, Kuklin N, Rouse BT. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J Gen Virol 1997;78(Pt 2): 427-34
106. Bernstein D. Glycoprotein D adjuvant herpes simplex virus vaccine. Expert Rev Vaccines 2005;4(5):615-27
107. Higgins TJ, Herold KM, Arnold RL, et al. Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J Infect Dis 2000; 182(5):1311-20
108. Available from: http://www.gsk.com/media/press-releases/2010/gsk- provides-update-on-herpevac-trial-for-women-evaluating-simplirix-herpes-simplex- vaccine.html 2010
109. Skinner GR, Fink C, Melling J, et al. Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol 1992;180(6):305-20
110. Skinner GR, Fink CG, Cowan M, et al. Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine. Med Microbiol Immunol 1987; 176(3):161-8
111. Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol 2011;85(7):3461-72
112. Dolan BP, Bennink JR, Yewdell JW. Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands. Cell Mol Life Sci 2011;68(9):1481-9
113. Yewdell JW, Schubert U, Bennink JR. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci 2001;114(Pt 5):845-51
114. Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204(3):595-603
115. Divito S, Cherpes TL, Hendricks RL. A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol Res 2006;36(1-3):119-26
116. Khanna KM, Lepisto AJ, Hendricks RL. Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol 2004;25(5):230-4
117. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985;151(3):420-36
118. Wharton M, Cochi SL, Williams WW. Measles, mumps, and rubella vaccines. Infect Dis Clin North Am 1990;4(1):47-73
119. Mundle ST, Hernandez H, Hamberger J, et al. High-purity preparation of HSV-2 vaccine candidate ACAM529 is immunogenic and efficacious in vivo. PLoS One 2013;8(2):e57224
120. Da Costa X, Kramer MF, Zhu J, et al. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000;74(17):7963-71
121. Ali SA, McLean CS, Boursnell ME, et al. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. Cancer Res 2000;60(6):1663-70
122. Xiang Z, He Y. Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology. BMC Bioinformatics 2013;14(Suppl 4):S2
123. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012;491:463-7
124. Hu K, He X, Yu F, et al. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis. Immunol Invest 2011;40(3):265-78
125. Awasthi S, Lubinski JM, Eisenberg RJ, et al. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine 2008;26(9):1195-203
126. Mihailescu R, Vitzu M, Brestoiu S. Treatment and prophylaxis of recurrent genital herpes using vaccinia immunostimulant (Antiherpin). Arch Roum Pathol Exp Microbiol 1990;49(4):315-21
127. Skinner GR, Buchan A, Davies J, et al. A virus-particle vaccine prepared from bovine mammillitis virus against herpes genitalis. Comp Immunol Microbiol Infect Dis 1991;14(2):133-50
128. Moller A, Andersen PL, Korsager B, Black FT. [Yellow fever vaccination as prophylaxis of herpes labialis]. Ugeskr Laeger 1997;159(15):2228-9
129. Schoub BD. Polio vaccine for the treatment of recurrent herpes simplex infections. S Afr Med J 1991;79(10):623
130. Use of oral poliovirus vaccine for unlicensed indications. CMAJ 1991;145(6):661
131. Wu JJ, Huang DB, Tyring SK. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 2004;64(2):79-83
132. Pyles RB, Higgins D, Chalk C, et al. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol 2002;76(22):11387-96
133. The-HSV-040-Study-Group. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial. Vaccine 2013; 31(51):6136-43
134. Tavares F, Cheuvart B, Heineman T, et al. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine. Vaccine 2013;31(13): 1759-64
135. Leroux-Roels G, Clement F, Vandepapeliere P, et al. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. Hum Vaccin Immunother 2013;9(6):1254-62
136. Dervillez X, Qureshi H, Chentoufi AA, et al. Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes. J Immunol 2013;191(10):5124-38
137. Santana VC, Diniz MO, Cariri FA, et al. Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8(+) T cell responses and protective immunity. PLoS One 2013;8(8): e71322
138. de Bruyn G, Vargas-Cortez M, Warren T, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006; 24(7):914-20
139. Douglas JM, Vontver LA, Stamm WE, et al. Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes. Antimicrob Agents Chemother 1985;27(2):203-6
140. Fanta D, Dostal V, Reiss-Gutfreund R. [BCG therapy of recurrent herpes simplex type 1 and 2 (HSV-1 and 2)]. Z Hautkr 1977;52(21):1099-104
141. Smolin G, Okumoto M, Meyer R, Belfort R Jr. Effect of immunization with attenuated Mycobacterium bovis (BCG) on experimental herpetic keratitis. Can J Ophthalmol 1975;10(3):385-90
142. Anderson FD, Ushijima RN, Larson CL. Recurrent herpes genitalis. Treatment with Mycobacterium bovis (BCG). Obstet Gynecol 1974;43(6):797-805
143. Macotela E, Alvarez-de la Rocha JB, Castillo-Rodriguez R, et al. [Management of recurrent genital herpes simplex with the Sabin triple vaccine]. Gac Med Mex 1979; 115(10):461-3
144. Garrel J, Millet P, Sonneck JM, et al. [Recurrent herpes: treatment using trivalent oral polio vaccine (author's transl)]. Nouv Presse Med 1979;8(1):47
145. Bierman SM. Sabin's poliomyelitis vaccine in recurrent herpes simplex. Arch Dermatol 1978;114(7):1094-5
146. Schoub BD. Smallpox vaccine for the treatment of recurrent herpes infection. S Afr Med J 1982;62(7):189
147. Kern AB, Schiff BL. Smallpox vaccinations in the management of recurrent herpes simplex: a controlled evaluation. J Invest Dermatol 1959;33:99-102
148. Le Goaster J, Gonzalo S, Bourée P, et al. Efficacy of the anti-VZV vaccine in HSV1 and HSV2 recurrent herpes simplex disease: a prospective study. Open Access J Clin Trials 2012;4:51-8
149. Dunning R. Some observations on vaccination, and the inoculated cow-pox. London: 1800
150. Lagrange PH, Hurtrel B, Stach JL. Vaccines against mycobacteria and other intracellular multiplying bacteria. Ann Inst Pasteur Immunol 1985;136D(2):151-62
151. Waters WR, Palmer MV, Buddle BM, Vordermeier HM. Bovine tuberculosis vaccine research: historical perspectives and recent advances. Vaccine 2012;30(16): 2611-22
152. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990;162(2):313-21
153. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008;205(1):7-12
154. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science 2007; 318(5853):1048-9
155. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007;318(5847):28-9
156. Gray G, Buchbinder S, Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010; 5(5):357-61
157. Casanova G, Cancela R, Alonzo L, et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002;70(4):235-9
158. Available from: http://www.businesswire. com/news/home/20100304005137/en/ BioVex-Initiates-Phase-1-Clinical-Trial-Genital#.Uu6TQRAWK-o 2010
159. Singh M, Carlson JR, Briones M, et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 1998;16(19):1822-7
160. Wizel B, Persson J, Thorn K, et al. Nasal and skin delivery of IC31((R))-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Vaccine 2012;30(29):4361-8
161. Kniskern PJ, Miller WJ. Hepatitis B vaccines: blueprints for vaccines of the future. Biotechnology 1992;20:177-204
162. Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol 2011; 269(1):5-9
163. Halford WP. Towards an effective genital herpes vaccine: past lessons and future prospects. Future Virol 2007;2(1):1-6
164. Cockburn WC. The use of mixed diphtheria-pertussis-tetanus antigens. Bull World Health Organ 1955;13(3):409-22
165. Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 2004;70: 1-14
166. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008;59:381-95
167. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003; 16(1):96-113
168. Knickelbein JE, Khanna KM, Yee MB, et al. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 2008;322(5899):268-71
169. Khanna K, Bonneau R, Kinchington P, Hendricks R. Herpes simplex virus-specific memory CD8(+) T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003;18(5): 593-603
170. Liu T, Khanna KM, Chen X, et al.8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 2000;191(9): 1459-66
171. Speck P, Simmons A. Precipitous clearance of herpes simplex virus antigens from the peripheral nervous systems of experimentally infected C57BL/10 mice. J Gen Virol 1998; 79(Pt 3):561-4
172. Simmons A, Tscharke DC. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med 1992;175(5):1337-44
173. Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. Febs J 2009; 276(24):7228-36
174. Nara PL, Lin G. HIV-1: the confounding variables of virus neutralization. Curr Drug Targets Infect Disord 2005;5(2):157-70
175. Araujo LA, Almeida SE. HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition. Viruses 2013;5(2): 595-604
176. Luo M. Influenza virus entry. Adv Exp Med Biol 2012;726:201-21
177. Nagafuchi S, Oda H, Mori R, Taniguchi T. Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice. J Gen Virol 1979;44(3):715-23
178. Oakes JE. Role for cell-mediated immunity in the resistance of mice to subcutaneous herpes simplex virus infection. Infect Immun 1975;12(1):166-72
179. Halford WP, Maender JL, Gebhardt BM. Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1. Virol J 2005;2:56
180. Theil D, Derfuss T, Paripovic I, et al. Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol 2003;163(6):2179-84
181. Morrison LA. Vaccines against genital herpes: progress and limitations. Drugs 2002;62(8):1119-29
182. Morrison LA, Zhu L, Thebeau LG. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J Virol 2001; 75(3):1195-204
183. Chu CF, Meador MG, Young CG, et al. Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and-independent mechanisms. J Reprod Immunol 2008;78(1):58-67
184. Staats HF, Oakes JE, Lausch RN. Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice
185. Mackay LK, Stock AT, Ma JZ, et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012;109(18):7037-42
186. Available from: http://www.niaid.nih.gov/news/newsreleases/2013/Pages/ HSV11-8-13.aspx 2013
187. Morrison LA, Da Costa XJ, Knipe DM. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 1998;243(1):178-87
188. Reszka NJ, Dudek T, Knipe DM. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 2010;28(15): 2754-62
189. Da Costa XJ, Jones CA, Knipe DM. Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci USA 1999;96(12):6994-8
190. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953;171(4356):737-8
191. Crick FH. On protein synthesis. Symp Soc Exp Biol 1958;12:138-63
192. Schmid DS. Varicella-zoster virus vaccine: molecular genetics. Curr Top Microbiol Immunol 2010;342:323-40
193. Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One 2008;3(10): e3433
194. Nahmias AJ, Naib ZM, Josey WE. Epidemiological studies relating genital herpetic infection to cervical carcinoma. Cancer Res 1974;34(5):1111-17
195. Manos JP, Walker EM Jr. Viruses and human cancer. Ann Clin Lab Sci 1983; 13(3):201-6
196. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24(Suppl 3):S3/1-10
197. Halford WP, Schaffer PA. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency. J Virol 2001;75(7):3240-9
198. Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 2000;6(4):451-4
199. Takahashi M, Okuno Y, Otsuka T, et al. Development of a live attenuated varicella vaccine. Biken J 1975;18(1):25-33
200. Goulleret N, Mauvisseau E, Essevaz-Roulet M, et al. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine 2010;28(36): 5878-82
201. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284(10):1271-9
202. Yamada M, Kamberos N, Grose C. Breakthrough varicella in a cancer patient with persistent varicella antibody after one varicella vaccination. J Pediatr 2013;163(5): 1511-13
203. Fisher JP, Bate J, Hambleton S. Preventing varicella in children with malignancies: what is the evidence? Curr Opin Infect Dis 2011; 24(3):203-11
204. Banovic T, Yanilla M, Simmons R, et al. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. J Infect Dis 2011;204(12):1893-901
205. Chilek K, Routhouska S, Tamburro J. Disseminated varicella zoster virus in an immunized child as the acquired immunodeficiency syndrome-defining illness. Pediatr Dermatol 2010;27(2): 192-4
206. Harle P, Sainz B Jr, Carr DJ, Halford WP. The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/beta. Virology 2002;293(2):295-304
207. Mossman KL, Saffran HA, Smiley JR. Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol 2000; 74(4):2052-6
208. Leib DA, Harrison TE, Laslo KM, et al. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 1999;189(4):663-72
209. Everett RD, Boutell C, McNair C, et al. Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins. J Virol 2010;84(7):3476-87
210. Moffat JF, Zerboni L, Kinchington PR, et al. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 1998;72(2):965-74
211. Zerboni L, Hinchliffe S, Sommer MH, et al. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 2005;332(1):337-46
212. Horien C, Grose C. Neurovirulence of varicella and the live attenuated varicella vaccine virus. Semin Pediatr Neurol 2012; 19(3):124-9
213. Prichard MN, Kaiwar R, Jackman WT, et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005; 23(46-47):5424-31
214. Stephenson J. Genital herpes vaccine shows limited promise. JAMA 2000;284(15): 1913-14
215. Wagner EK. 2000. Available from: http://darwin.bio.uci.edu/~faculty/ wagner/hsv3f.html